Masimo Stock

Masimo Equity

Delisted·Jun 12, 2026

The The Equity of Masimo (MASI) as of Aug 1, 2026 is 721.20 M USD. In the previous year, The Equity was 1.05 B USD — a change of -31.44% (lower).

Equity

721.20 MUSD

YoY

-31.44%

Last updated:

In 2026, Masimo's equity was 721.20 M USD, a -31.44% increase from the 1.05 B USD equity in the previous year.

Access this data via the Eulerpool API

Masimo Stock analysis

What does Masimo do? Masimo Corporation is an American medical technology company based in Irvine, California. The company was founded in 1989 by Professor Joe Kiani, who is still the chairman and CEO of the company today. With innovative products and advanced technology, Masimo aims to optimize medical diagnostic and treatment procedures to improve patient care. The business model of Masimo Corp focuses on developing and marketing products and solutions for patient monitoring and treatment in hospitals, intensive care facilities, and outpatient clinics. The company relies on high levels of innovation and collaboration with physicians, scientists, and other experts. The goal is to improve existing medical procedures, explore new applications for the technology, and optimize patient care. Masimo Corp's products are divided into different divisions that focus on various aspects of medical care. One example is the "Patient Monitoring" division, which offers various monitoring systems for vital signs such as respiration, pulse, and oxygen saturation. This includes products like the Rad-67 pulse oximeter or the Root patient monitor, which continuously monitor patients during treatment to enhance safety and effectiveness. Another division is "Anesthesia and Sedation," which focuses on solutions for anesthesiologists and intensive care specialists. Masimo Corp offers products such as the SedLine brain monitor or the EMMA main gas monitor, which enable physicians to control anesthesia depth more precisely and reduce the risk of complications. In addition to patient monitoring systems, Masimo Corp also provides solutions for neonatal care. The "Neonatal Care" division includes products like the Masimo Radical-7 pulse oximeter for monitoring premature infants or the Pronto-7 pulse oximeter for fast and accurate monitoring of newborns in the delivery room. Furthermore, Masimo Corp has developed products for monitoring surgical patients. The "Surgical and Minimally Invasive Monitoring" division, for example, offers the MOC-9 monitoring system for precise monitoring of hemodynamics during surgery. A unique product of Masimo Corp is also the Masimo SET sensor, which provides more accurate and reliable measurement of blood oxygen saturation than traditional pulse oximeter sensors. The company has filed over 100 patents worldwide for this technology and has been recognized with numerous awards and accolades. In summary, Masimo Corp is an innovative company specializing in improving medical care through the development and marketing of products for patient monitoring and treatment. With its state-of-the-art technologies and collaboration with experts in medical research, Masimo Corp sets standards for patient safety and treatment effectiveness. Masimo is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Masimo's Equity

Masimo's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Masimo's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Masimo's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Masimo's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Masimo’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Masimo stock

The Equity of Masimo is 721.20 M USD in 2026.

Access this data via the Eulerpool API

Balance Sheet — Masimo

All Key Metrics — Masimo